Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 87.79
Day High 89.27
Open:89.13
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Abbvie Inc Up 24.5% Since SmarTrend Uptrend Call (ABBV)
- Comtex SmarTrend(R) - Sat Jan 18, 4:25AM CST
Comtex SmarTrend(R) - CMTX
Sat Jan 18, 4:25AM CST
SmarTrend identified an Uptrend for Abbvie Inc (NYSE:ABBV) on September 12th, 2019 at $70.68. In approximately 4 months, Abbvie Inc has returned 24.50% as of today's recent price of $88.00.
Global Heart Transplantation Therapeutics Market 2020-2024: AbbVie Inc, Mylan NV, Pfizer Inc & Teva Pharmaceutical Industries Ltd - ResearchAndMarkets.com
- BusinessWire - Wed Jan 15, 4:47AM CST
BusinessWire - CMTX
Wed Jan 15, 4:47AM CST
The "Heart Transplantation Therapeutics Market by Product and Geography - Forecast and Analysis 2020-2024" report has been added to ResearchAndMarkets.com's offering.
New Head-to-Head Phase 3 Data Show SKYRIZI(TM) (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks
- PR Newswire - Tue Jan 14, 7:45AM CST
PR Newswire - CMTX
Tue Jan 14, 7:45AM CST
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that SKYRIZI(TM) met both primary and all ranked secondary endpoints, including superiority at week 52, versus Cosentyx® in a head-to-head Phase 3 study.1 SKYRIZI showed significantly higher rates of skin clearance compared to Cosentyx, meeting the primary endpoint of superiority with at least a 90 percent improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) at week 52.1 Of patients treated with SKYRIZI, 87 percent achieved PASI 90 compared to 57 percent of Cosentyx-treated patients at 52 weeks (p<0.001).1 At week 16, SKYRIZI also met the other primary endpoint of non-inferiority to Cosentyx with 74 percent of SKYRIZI patients achieving PASI 90 compared to 66 percent of Cosentyx patients.1
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 86.77 +1.42% increase
on 01/14/20
Period Open:90.08
Price movement based on the high, low and last over the given period.
91.99 -4.34% decrease
on 12/20/19
-2.08 (-2.31%) decrease
since 12/17/19
3-Month 75.21 +17.01% increase
on 10/18/19
Period Open:75.14
Price movement based on the high, low and last over the given period.
91.99 -4.34% decrease
on 12/20/19
+12.86 (+17.11%) increase
since 10/17/19
52-Week 62.66 +40.44% increase
on 08/15/19
Period Open:87.20
Price movement based on the high, low and last over the given period.
91.99 -4.34% decrease
on 12/20/19
+0.80 (+0.92%) increase
since 01/17/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies